DPP‐4 inhibitors, such as sitagliptin, alogliptin, vildagliptin, saxagliptin and linagliptin, which selectively inhibit the catalytic activity of cell‐associated and circulating soluble DPP‐4, are widely used drugs against diabetes. Here, DPP4 is linked to diabetes mellitus.